- Home
- GRND vs RCKT Comparison
GRND vs RCKT Comparison
Compare GRND & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- RCKT
- Stock Information
- Founded
- GRND 2009
- RCKT 1999
- Country
- GRND United States
- RCKT United States
- Employees
- GRND N/A
- RCKT N/A
- Industry
- GRND Computer Software: Prepackaged Software
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- GRND Technology
- RCKT Health Care
- Exchange
- GRND Nasdaq
- RCKT Nasdaq
- Market Cap
- GRND 4.3B
- RCKT 264.0M
- IPO Year
- GRND N/A
- RCKT N/A
- Fundamental
- Price
- GRND $22.03
- RCKT $3.02
- Analyst Decision
- GRND Strong Buy
- RCKT Buy
- Analyst Count
- GRND 6
- RCKT 13
- Target Price
- GRND $23.50
- RCKT $18.50
- AVG Volume (30 Days)
- GRND 1.6M
- RCKT 4.0M
- Earning Date
- GRND 08-07-2025
- RCKT 08-04-2025
- Dividend Yield
- GRND N/A
- RCKT N/A
- EPS Growth
- GRND N/A
- RCKT N/A
- EPS
- GRND N/A
- RCKT N/A
- Revenue
- GRND $363,229,000.00
- RCKT N/A
- Revenue This Year
- GRND $28.97
- RCKT N/A
- Revenue Next Year
- GRND $21.80
- RCKT N/A
- P/E Ratio
- GRND N/A
- RCKT N/A
- Revenue Growth
- GRND 30.08
- RCKT N/A
- 52 Week Low
- GRND $10.26
- RCKT $2.19
- 52 Week High
- GRND $25.13
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- GRND 43.55
- RCKT 45.25
- Support Level
- GRND $21.52
- RCKT $2.76
- Resistance Level
- GRND $22.73
- RCKT $2.96
- Average True Range (ATR)
- GRND 0.64
- RCKT 0.20
- MACD
- GRND -0.05
- RCKT 0.16
- Stochastic Oscillator
- GRND 29.19
- RCKT 88.57
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.